Skip to main content
Caplight Logo









Azafaros

Azafaros

Private
LeidenHealthcare & Life Scienceshttps://www.azafaros.com/

Last Round

Series B

May 13, 2025

Total Funding Raised

$174.14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Azafaros is a biopharmaceutical company developing disease-modifying therapeutics for rare lysosomal storage disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrare metabolic diseasessmall moleculelysosomal storage disordersorphan drugsblood-brain barrierclinical-stage biotechdrug discoveryGM2 gangliosidosisNiemann-Pick diseasebiopharmaclinical trialsdrug developmentmetabolic disordersCNS therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Azafaros Comparables

Compare Azafaros with similar companies based on industry and business-model similarity.

Azafaros comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IntraBio
84%
Mandos
79%
Polaryx Therapeutics
78%

Azafaros Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2025
Series AFeb 6, 2020
SeedJul 23, 2018

Key People

Founding team and executive leadership

Stefano Portolano

Chief Executive Officer

Executive Team

Silvia Ragno

Chief Operating Officer

Executive Team

Azafaros Investors

Notable investors and investment history

Azafaros investors
InvestorRounds
Pictet GroupSeries B
Asahi Kasei Pharma Venture CapitalSeries B
BioMedPartnersSeries B, Series A
Asahi Kasei Therapeutics Venture CapitalSeries B
ForbionSeries B, Series A
Seroba Life SciencesSeries B
Forbion VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 204% MoM, reaching 3.9K.

  • Jan 8, 2026

    Will present at J.P. Morgan's 44th Annual Healthcare Conference.

Azafaros Filings

Explore SEC and related filing metadata, where available.

Azafaros filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Azafaros's valuation, stock price, and market status.

Is Azafaros a public or private company?

Azafaros is a private company.

What is the current stock price of Azafaros?

Azafaros is a private company with no public stock price. No recent secondary market data is available.

How much is Azafaros worth (valuation)?

Valuation information for Azafaros is not publicly available.

Can I buy Azafaros stock?

Azafaros shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Azafaros's last funding round?

Azafaros's most recent funding round was Series B on May 13, 2025.

Who are the main investors in Azafaros?

Key investors in Azafaros include Forbion, BioGeneration Ventures, Jeito.

Will Azafaros IPO soon?

No public IPO plans have been announced for Azafaros.

How can I track Azafaros secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Azafaros's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeiden
Employee Range28
Year Founded2018
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?